From Chaos To Clarity: A Founder's View From 30 Years In Drug Development

Clinical trial outcomes are shaped by more than target biology and study design. They also depend on how accurately and consistently protocol-critical work is carried out at clinical sites.

In this fireside chat, Dr. Richard Graham brings that point into focus, drawing on three decades in drug development and firsthand experience across programs that led to five approved therapies.

While therapeutic modalities have advanced dramatically over the course of Rick’s career, many of the workflows used to run clinical trials, particularly around biological sample collection and handling, have changed very little. These outdated processes continue to introduce avoidable scientific, regulatory, and ethical risk, often in ways sponsors cannot see until late in a program.

The conversation covers:

• The regulatory review moments that made biological sample handling impossible for Rick to ignore
• How lost, switched, or unusable samples can affect trial data and study interpretation
• Why many sample-related issues begin at the point of collection
• How better execution visibility can help sponsors support sites and protect study outcomes